Healthcare Industry News: radiosurgery
News Release - July 26, 2009
Accuray Announces CyberKnife Access Remote Service ProductPurchase of Axeda ServiceLink Solution Enables Fast and Effective Servicing
SUNNYVALE, Calif., July 26 (Healthcare Sales & Marketing Network) -- Accuray Incorporated (Nasdaq: ARAY ), a global leader in the field of radiosurgery, announced today the launch of the CyberKnife Access(TM) Remote Service product, a real-time customer service and support offering for the CyberKnife(R) Robotic radiosurgery System. This and other Accuray technologies will be highlighted during the 51st Annual Meeting of The American Association of Physicists in Medicine, July 26-30, 2009 in Anaheim, Calif.
CyberKnife Access utilizes the Axeda(R)ServiceLink technology to provide a remote service solution for the devices that make up CyberKnife Systems at customer sites. This Remote Service offering enables Accuray's team of highly trained engineers and customer support technicians to diagnose and address service needs from a remote location using a secure internet connection. The result is real-time support, allowing for a quick customer response without a site visit, thereby enhancing operational efficiencies.
"With CyberKnife Access a simple issue can be diagnosed remotely so that a replacement part can be ordered before the engineer even arrives on site," said Jeff Snyder, manager of Radiation Oncology and CyberKnife at Southwest Washington Medical Center in Vancouver, Wash. "It's reassuring to know that when you have a patient coming in for treatment and a service need arises, a lifeline exists so you can get their treatment going without delay."
"We strive to provide the highest level of service and support to our customers," said Chris Raanes, senior vice president and chief operating officer at Accuray. "With CyberKnife Access, we're now able to provide faster and easier servicing to help our customers resume treatments with minimal interruptions to patient care."
Axeda has delivered remote service solutions to more than 20 of the world's leading medical and life science manufacturers. Axeda ServiceLink enables companies to securely monitor the health and performance of their products from anywhere in the world, while helping them comply with industry regulations such as HIPAA and 21 CFR Part 11.
Axeda Corporation delivers secure remote service and support capabilities to some of the world's leading manufacturing companies and large enterprises. The award-winning Axeda ServiceLink solution helps companies, including Abbott Laboratories, Diebold and EMC, proactively service and support products to drive optimal uptime at the lowest possible cost, while enabling enterprises to effectively secure, control and track all remote access to critical data centers. In 2006, Axeda became the first and only remote service application provider to receive the prestigious VeriSign(R) Security Certification. Axeda Corporation is a privately held company headquartered in Foxboro, Mass. and can be reached at www.axeda.com.
About the CyberKnife(R) Robotic radiosurgery System
The CyberKnife Robotic radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
Accuray Incorporated (Nasdaq: ARAY ), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 60,000 patients worldwide and currently more than 164 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to commercialization of products, clinical studies, and regulatory review and approval are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2008 fiscal year, as updated in our Form 10-Q filed on May 6, 2009 and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsPhase 3 Randomized Trial Data Shows SBRT has Similar Acute Safety Profile to Conventional Radiation Therapy in Patients with Localized Prostate Cancer
Accuray and China Isotope and Radiation Corporation Enter Joint Venture Contract to Manufacture and Sell Radiation Oncology Systems in China
Accuray CyberKnife(R) System Treatment Delivery Times Up to 50 Percent Faster With Software Upgrade